Tyrosine kinase inhibitorFDA-approvedSecond-line
Binimetinib
How it works
Blocks the MEK protein, which is involved in cell growth and division, and is often mutated in cancer cells.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 2.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Palbociclib and Binimetinib in RAS-Mutant Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| Combining Metformin and Binimetinib May Help Fight Melanoma | Melanoma | lab-study | — | Source → |
| MEK Inhibitor Shows Modest Effectiveness in Advanced Melanoma | Melanoma | observational | The disease control rate was 60.0%. | Source → |
| Study of Encorafenib and Binimetinib for BRAF Mutant Melanoma with Brain Metastasis | Melanoma | phase-2 | Treatment with encorafenib plus binimetinib demonstrated a brain metastasis response rate of over 60%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.